keyword
https://read.qxmd.com/read/38419163/transmission-and-non-transmission-of-melanoma-from-deceased-solid-organ-donors-to-transplant-recipients-risks-and-missed-opportunities
#1
JOURNAL ARTICLE
Brenda Maria Rosales, James Hedley, Nicole De La Mata, Elena Cavazzoni, Claire M Vajdic, John F Thompson, Patrick J Kelly, Kate Wyburn, Angela C Webster
BACKGROUND: Biovigilance concerns are in tension with the need to increase organ donation. Cancer transmission risk from donor to recipient may be overestimated, as non-transmission events are rarely reported. We sought to estimate melanoma transmission risk in deceased organ donation and identify missed opportunities for donation in an Australian cohort with high melanoma prevalence. METHODS: We used a population-based approach and linked deceased organ donors, transplant recipients, and potential donors forgone, 2010-2018, with the Central Cancer Registry (CCR), 1976-2018...
February 29, 2024: Transplantation
https://read.qxmd.com/read/38417447/nilotinib-in-kit-driven-advanced-melanoma-results-from-the-phase-ii-single-arm-nicam-trial
#2
JOURNAL ARTICLE
James Larkin, Richard Marais, Nuria Porta, David Gonzalez de Castro, Lisa Parsons, Christina Messiou, Gordon Stamp, Lisa Thompson, Kim Edmonds, Sarah Sarker, Jane Banerji, Paul Lorigan, Thomas R Jeffry Evans, Pippa Corrie, Ernest Marshall, Mark R Middleton, Paul Nathan, Steve Nicholson, Christian Ottensmeier, Ruth Plummer, Judith Bliss, Sara Valpione, Samra Turajlic
Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This multicenter, single-arm Phase II trial (NICAM) investigates nilotinib safety and activity in KIT mutated metastatic MM and AM. KIT mutations are identified in 39/219 screened patients (18%); of 29/39 treated, 26 are evaluable for primary analysis. Six patients were alive and progression free at 6 months (local radiology review, 25%); 5/26 (19%) had objective response at 12 weeks; median OS was 7...
February 16, 2024: Cell reports medicine
https://read.qxmd.com/read/38319662/smoking-status-and-survival-in-patients-with-early-stage-primary-cutaneous-melanoma
#3
JOURNAL ARTICLE
Katherine M Jackson, Peter C Jones, Laura M Fluke, Trevan D Fischer, John F Thompson, Alistair J Cochran, Stacey L Stern, Mark B Faries, Dave S B Hoon, Leland J Foshag
IMPORTANCE: While smoking is associated with a decreased incidence of cutaneous melanoma, the association of smoking with melanoma progression and death is not well defined. OBJECTIVE: To determine the association of smoking with survival in patients with early-stage primary cutaneous melanoma. DESIGN, SETTING, AND PARTICIPANTS: This cohort study performed a post hoc analysis of data derived from the randomized, multinational first and second Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II)...
February 5, 2024: JAMA Network Open
https://read.qxmd.com/read/38315961/predicting-recurrence-free-and-overall-survival-for-patients-with-stage-ii-melanoma-the-mia-calculator
#4
JOURNAL ARTICLE
Alexander H R Varey, Isabel Li, Mary-Ann El Sharouni, Julie Simon, Aikaterini Dedeilia, Sydney Ch'ng, Robyn P M Saw, Andrew J Spillane, Kerwin F Shannon, Thomas E Pennington, Michael Rtshiladze, Jonathan R Stretch, Omgo E Nieweg, Alexander van Akkooi, Ryan J Sullivan, Genevieve M Boland, Jeffrey E Gershenwald, Paul J van Diest, Richard A Scolyer, Georgina V Long, John F Thompson, Serigne N Lo
PURPOSE: Improvements in recurrence-free survival (RFS) were demonstrated in two recent randomized trials for patients with sentinel node (SN)-negative stage IIB or IIC melanoma receiving adjuvant systemic therapy (pembrolizumab/nivolumab). However, adverse events also occurred. Accurate individualized prognostic estimates of RFS and overall survival (OS) would allow patients to more accurately weigh the risks and benefits of adjuvant therapy. Since the current American Joint Committee on Cancer eighth edition (AJCC-8) melanoma staging system focuses on melanoma-specific survival, we developed a multivariable risk prediction calculator that provides estimates of 5- and 10-year RFS and OS for these patients...
February 5, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38309721/efficacy-and-safety-of-autologous-tumor-infiltrating-lymphocytes-in-recurrent-or-refractory-ovarian-cancer-colorectal-cancer-and-pancreatic-ductal-adenocarcinoma
#5
JOURNAL ARTICLE
Rodabe Amaria, Anne Knisely, David Vining, Scott Kopetz, Michael J Overman, Milind Javle, Mara B Antonoff, Ching-Wei D Tzeng, Robert A Wolff, Shubham Pant, Kathryn Lito, Kelly Rangel, Bryan Fellman, Ying Yuan, Karen H Lu, Donastas Sakellariou-Thompson, Cara L Haymaker, Marie-Andrée Forget, Patrick Hwu, Chantale Bernatchez, Amir A Jazaeri
BACKGROUND: Tumor-infiltrating lymphocyte (TIL) therapy has shown efficacy in metastatic melanoma, non-small cell lung cancer, and other solid tumors. Our preclinical work demonstrated more robust CD8 predominant TIL production when agonistic anti-4-1BB and CD3 antibodies were used in early ex vivo TIL culture. METHODS: Patients with treatment-refractory metastatic colorectal (CRC), pancreatic (PDAC) and ovarian (OVCA) cancers were eligible. Lymphodepleting chemotherapy was followed by infusion of ex vivo expanded TIL, manufactured at MD Anderson Cancer Center with IL-2 and agonistic stimulation of CD3 and 4-1BB (urelumab)...
February 2, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38224912/superficial-x-ray-in-the-treatment-of-non-aggressive-basal-and-squamous-cell-carcinoma-in-the-elderly-a-22-year-retrospective-analysis
#6
JOURNAL ARTICLE
Alexzandra Mattia, Anthony Thompson, Sang Kyu Lee, Hyokyoung G Hong, William Harris Green, Armand B Cognetta
No abstract text is available yet for this article.
January 13, 2024: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/38198163/population-based-validation-of-the-mia-and-mskcc-tools-for-predicting-sentinel-lymph-node-status
#7
JOURNAL ARTICLE
Roger Olofsson Bagge, Rasmus Mikiver, Michael A Marchetti, Serigne N Lo, Alexander C J van Akkooi, Daniel G Coit, Christian Ingvar, Karolin Isaksson, Richard A Scolyer, John F Thompson, Alexander H R Varey, Sandra L Wong, Johan Lyth, Edmund K Bartlett
IMPORTANCE: Patients with melanoma are selected for sentinel lymph node biopsy (SLNB) based on their risk of a positive SLN. To improve selection, the Memorial Sloan Kettering Cancer Center (MSKCC) and Melanoma Institute Australia (MIA) developed predictive models, but the utility of these models remains to be tested. OBJECTIVE: To determine the clinical utility of the MIA and MSKCC models. DESIGN, SETTING, AND PARTICIPANTS: This was a population-based comparative effectiveness research study including 10 089 consecutive patients with cutaneous melanoma undergoing SLNB from the Swedish Melanoma Registry from January 2007 to December 2021...
January 10, 2024: JAMA Surgery
https://read.qxmd.com/read/38117390/aso-visual-abstract-role-of-concurrent-ultrasound-surveillance-of-sentinel-node-positive-node-fields-in-melanoma-patients-having-routine-cross-sectional-imaging
#8
JOURNAL ARTICLE
Caroline A Gjorup, Rachel Woodford, Isabel Li, Matteo S Carlino, Sydney Ch'ng, David Chung, Edward Hsiao, Serigne N Lo, Kevin London, Georgina V Long, Alexander M Menzies, Omgo E Nieweg, Thomas E Pennington, Michael A Rtshiladze, Robyn P M Saw, Richard A Scolyer, Kerwin F Shannon, Andrew J Spillane, Jonathan R Stretch, John F Thompson, Alexander H R Varey, Alexander C J van Akkooi
No abstract text is available yet for this article.
December 20, 2023: Annals of Surgical Oncology
https://read.qxmd.com/read/37979010/correction-to-extended-duration-of-treatment-using-reduced%C3%A2-frequency-dosing-of-anti%C3%A2-pd%C3%A2-1-therapy-in-patients-with-advanced-melanoma-and-merkel-cell-carcinoma
#9
Lisa May Ling Tachiki, Daniel S Hippe, Karly Williams Silva, Evan Thomas Hall, William McCamy, Dane Fritzsche, Andrea Perdue, Julia Majovski, Thomas Pulliam, Daniel A Goldstein, Joshua Veatch, Joel Ho, Paul T Nghiem, John A Thompson, Shailender Bhatia
No abstract text is available yet for this article.
November 18, 2023: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/37966706/role-of-concurrent-ultrasound-surveillance-of-sentinel-node-positive-node-fields-in-melanoma-patients-having-routine-cross-sectional-imaging
#10
JOURNAL ARTICLE
Caroline A Gjorup, Rachel Woodford, Isabel Li, Matteo S Carlino, Sydney Ch'ng, David Chung, Edward Hsiao, Serigne N Lo, Kevin London, Georgina V Long, Alexander M Menzies, Omgo E Nieweg, Thomas E Pennington, Michael A Rtshiladze, Robyn P M Saw, Richard A Scolyer, Kerwin F Shannon, Andrew J Spillane, Jonathan R Stretch, John F Thompson, Alexander H R Varey, Alexander C J van Akkooi
PURPOSE: In sentinel node-positive (SN+ve) melanoma patients, active surveillance with regular ultrasound examination of the node field has become standard, rather than completion lymph node dissection (CLND). A proportion of these patients now receive adjuvant systemic therapy and have routine cross-sectional imaging (computed tomography [CT] or positron emission tomography [PET]/CT). The role of concurrent ultrasound (US) surveillance in these patients is unclear. The purpose of our study was to describe the modality of detection of nodal recurrence in SN+ve node fields...
November 15, 2023: Annals of Surgical Oncology
https://read.qxmd.com/read/37930181/telehealth-follow-up-consultations-for-melanoma-patients-during-the-covid-19-pandemic-patient-and-clinician-satisfaction
#11
JOURNAL ARTICLE
Ali Al-Rikaby, Ahmad Sulaiman, Jake R Thompson, Robyn P M Saw, Frances Boyle, Nicole Taylor, Matteo S Carlino, Rachael L Morton, Omgo E Nieweg, John F Thompson, Iris Bartula
INTRODUCTION: The COVID-19 pandemic caused rapid implementation of telehealth for melanoma follow-up care in Australia. This study explores Australian melanoma patients and clinicians' level of satisfaction with telehealth. METHODS: A cross-sectional study was conducted across three specialist melanoma centres in Sydney, Australia. Melanoma patients (all stages) and clinicians completed mixed methods surveys seeking socio-demographic and clinical information and questionnaires to assess satisfaction with telehealth...
November 6, 2023: Cancer Medicine
https://read.qxmd.com/read/37910123/prognostic-significance-of-incipient-ulceration-in-primary-cutaneous-melanoma
#12
JOURNAL ARTICLE
Elizabeth C Paver, Tasnia Ahmed, Hazel Burke, Robyn P M Saw, Jonathan R Stretch, Andrew J Spillane, Kerwin F Shannon, Ismael A Vergara, David E Elder, Serigne N Lo, John F Thompson, Richard A Scolyer
IMPORTANCE: Ulceration represents a key feature in cutaneous melanoma, contributing to staging according to the current American Joint Committee on Cancer (AJCC) system. However, cases with incipient ulceration do not quite fulfill the AJCC definition of ulceration and are consequently classified as nonulcerated, presenting interpretive difficulty for pathologists. The prognostic implication of incipient ulceration is uncertain. OBJECTIVE: To evaluate the prognostic significance of incipient ulceration in cutaneous melanoma...
December 1, 2023: JAMA Dermatology
https://read.qxmd.com/read/37907221/first-in-human-phase-i-ib-study-of-niz985-a-recombinant-heterodimer-of-il-15-and-il-15r%C3%AE-as-a-single-agent-and-in-combination-with-spartalizumab-in-patients-with-advanced-and-metastatic-solid-tumors
#13
JOURNAL ARTICLE
Rom Leidner, Kevin Conlon, Douglas G McNeel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A O'Keeffe, Nancy Lewis, George N Pavlakis, John A Thompson
BACKGROUND: Preclinically, interleukin-15 (IL-15) monotherapy promotes antitumor immune responses, which are enhanced when IL-15 is used in combination with immune checkpoint inhibitors (ICIs). This first-in-human study investigated NIZ985, a recombinant heterodimer comprising physiologically active IL-15 and IL-15 receptor α, as monotherapy and in combination with spartalizumab, an anti-programmed cell death protein-1 (anti-PD-1) monoclonal antibody, in patients with advanced solid tumors...
October 2023: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/37804644/harold-gillies-pioneer-of-modern-plastic-surgery-and-donald-morton-pioneer-of-modern-surgical-oncology-master-problem-solvers-and-surgical-role-models
#14
REVIEW
J F Thompson
Harold Gillies, plastic surgeon, and Donald Morton, surgical oncologist, were iconic pioneers in their respective fields. Both of them made their mark by identifying crucial practical problems and finding innovative ways of solving them. Gillies grappled with the challenge of restoring form and function to British military personnel injured in World War I, and he set up a dedicated facility for performing this work. He introduced many new reconstructive techniques that became the foundation of the modern specialty of plastic and reconstructive surgery, which he established and nurtured...
September 15, 2023: Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS
https://read.qxmd.com/read/37789011/uncovering-the-complex-relationship-between-balding-testosterone-and-skin-cancers-in-men
#15
JOURNAL ARTICLE
Jue-Sheng Ong, Mathias Seviiri, Jean Claude Dusingize, Yeda Wu, Xikun Han, Jianxin Shi, Catherine M Olsen, Rachel E Neale, John F Thompson, Robyn P M Saw, Kerwin F Shannon, Graham J Mann, Nicholas G Martin, Sarah E Medland, Scott D Gordon, Richard A Scolyer, Georgina V Long, Mark M Iles, Maria Teresa Landi, David C Whiteman, Stuart MacGregor, Matthew H Law
Male-pattern baldness (MPB) is related to dysregulation of androgens such as testosterone. A previously observed relationship between MPB and skin cancer may be due to greater exposure to ultraviolet radiation or indicate a role for androgenic pathways in the pathogenesis of skin cancers. We dissected this relationship via Mendelian randomization (MR) analyses, using genetic data from recent male-only meta-analyses of cutaneous melanoma (12,232 cases; 20,566 controls) and keratinocyte cancers (KCs) (up to 17,512 cases; >100,000 controls), followed by stratified MR analysis by body-sites...
October 3, 2023: Nature Communications
https://read.qxmd.com/read/37785636/image-guided-high-dose-rate-brachytherapy-for-definitive-management-of-primary-vaginal-cancer-a-single-institutional-experience
#16
JOURNAL ARTICLE
K Lichter, N Malik, P S Thompson, A Sabbagh, J A M Cunha, E J Yoshida, I C J Hsu
PURPOSE/OBJECTIVE(S): To assess the safety and efficacy of image-guided high-dose-rate brachytherapy (IGBT) alone or in combination with external beam radiation therapy (EBRT) for the treatment of vaginal cancers. MATERIALS/METHODS: The study analyzed patients diagnosed with primary vaginal cancers from 2004 to 2021 who received definitive radiotherapy at a single institution. Interstitial implants were performed using a freehand technique and transvaginal or transrectal-ultrasound for imaging guidance...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37750845/machine-learning-identification-of-patient-clusters-for-cutaneous-melanoma
#17
JOURNAL ARTICLE
Leo J Thompson, Al'ona Furmanchuk, Walter Liszewski, Abel Kho, Dennis P West, David M Liebovitz, Beatrice Nardone, Pedram Gerami
BACKGROUND: Cutaneous melanoma is a cancer arising in melanocyte skin cells and is the deadliest form of skin cancer worldwide. Although some risk factors are known, accurate prediction of disease progression and probability for metastasis are difficult to ascertain, given the complexity of the disease and the absence of reliable predictive markers. Since early detection and treatment are essential to enhance survival, this study utilizing machine learning (ML) aims to further delineate additional risk factors associated with cutaneous melanoma...
September 26, 2023: Italian journal of dermatology and venereology
https://read.qxmd.com/read/37733060/extended-duration-of-treatment-using-reduced-frequency-dosing-of-anti-pd-1-therapy-in-patients-with-advanced-melanoma-and-merkel-cell-carcinoma
#18
JOURNAL ARTICLE
Lisa May Ling Tachiki, Daniel S Hippe, Karly Williams Silva, Evan Thomas Hall, William McCamy, Dane Fritzsche, Andrea Perdue, Julia Majovski, Thomas Pulliam, Daniel A Goldstein, Joshua Veatch, Joel Ho, Paul T Nghiem, John A Thompson, Shailender Bhatia
BACKGROUND: Optimal duration of treatment (DoT) with immune checkpoint inhibitors (ICI) in metastatic cancers remains unclear. Many patients, especially those without radiologic complete remission, develop progressive disease after ICI discontinuation. Extending DoT with ICI may potentially improve efficacy outcomes but presents major logistical and cost challenges with standard frequency dosing (SFD). Receptor occupancy data supports reduced frequency dosing (RFD) of anti-PD-1 antibodies, which may represent a more practical and economically viable option to extend DoT...
September 21, 2023: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/37714220/prognosis-for-people-with-multiple-primary-melanomas-compared-with-a-single-primary-melanoma
#19
JOURNAL ARTICLE
Yuan Ni, Caroline G Watts, Richard A Scolyer, Christine Madronio, Bruce K Armstrong, Rachael L Morton, Scott W Menzies, Graham J Mann, John F Thompson, Anne E Cust, Serigne N Lo
No abstract text is available yet for this article.
September 13, 2023: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/37678496/factors-affecting-follow-up-adherence-following-mohs-micrographic-surgery-in-patients-with-non-melanoma-skin-cancer-a-retrospective-chart-review
#20
JOURNAL ARTICLE
Sumrah Jilani, Nina M D'Amiano, Katherine G Thompson, Jeremy Ellis, Anjali D'Amiano, Elena Wei, Kristin P Bibee, Jeffrey F Scott
No abstract text is available yet for this article.
September 5, 2023: Journal of the American Academy of Dermatology
keyword
keyword
58967
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.